Scale Market Report: Good Year for Small Values

Cantourage: Business is top, but now new requirements?

Regulatory headwinds are currently feared for Cantourage, the provider of medical cannabis. The share price rose to €6.68 in June, but is now down to €3.43. However, analyst firm Montega continues to recommend buying the stock, lowering its price target from €13 to €10. "While the draft legislation under discussion proposes restrictions such as a ban on mail-order sales, stricter rules for telemedicine, and expanded documentation requirements, the fundamental demand potential for medical cannabis in Germany remains unchanged," the analysts explain. NuWays also continues to recommend buying and considers the stock fairly valued at €10.50.